Enzymatica Balance Sheet Health
Financial Health criteria checks 3/6
Enzymatica has a total shareholder equity of SEK83.9M and total debt of SEK28.0M, which brings its debt-to-equity ratio to 33.4%. Its total assets and total liabilities are SEK137.1M and SEK53.1M respectively.
Key information
33.4%
Debt to equity ratio
kr28.01m
Debt
Interest coverage ratio | n/a |
Cash | kr26.92m |
Equity | kr83.93m |
Total liabilities | kr53.14m |
Total assets | kr137.07m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EN9's short term assets (SEK50.2M) exceed its short term liabilities (SEK27.8M).
Long Term Liabilities: EN9's short term assets (SEK50.2M) exceed its long term liabilities (SEK25.3M).
Debt to Equity History and Analysis
Debt Level: EN9's net debt to equity ratio (1.3%) is considered satisfactory.
Reducing Debt: EN9's debt to equity ratio has increased from 4.3% to 33.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EN9 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: EN9 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.1% each year